These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 14627730)
41. PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972 [TBL] [Abstract][Full Text] [Related]
42. [From gene to disease; the PABN1 gene and oculopharyngeal muscular dystrophy]. Schreuder AH; de Die-Smulders CE; Herbergs J; Koehler PJ Ned Tijdschr Geneeskd; 2006 May; 150(20):1124-6. PubMed ID: 16756225 [TBL] [Abstract][Full Text] [Related]
43. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313 [TBL] [Abstract][Full Text] [Related]
44. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Abu-Baker A; Rouleau GA Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089 [TBL] [Abstract][Full Text] [Related]
45. A Case of Oculopharyngeal Muscular Dystrophy Caused by a Novel PABPN1 c.34G > T (p.Gly12Trp) Point Mutation without Polyalanine Expansion. Takahashi Y; Morimoto N; Nada T; Morimoto M; Eura N; Minami N; Nishino I J Neuromuscul Dis; 2023; 10(3):459-463. PubMed ID: 36847015 [TBL] [Abstract][Full Text] [Related]
46. Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing. Klein P; Oloko M; Roth F; Montel V; Malerba A; Jarmin S; Gidaro T; Popplewell L; Perie S; Lacau St Guily J; de la Grange P; Antoniou MN; Dickson G; Butler-Browne G; Bastide B; Mouly V; Trollet C Nucleic Acids Res; 2016 Dec; 44(22):10929-10945. PubMed ID: 27507886 [TBL] [Abstract][Full Text] [Related]
47. Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein. Raz V; Routledge S; Venema A; Buijze H; van der Wal E; Anvar S; Straasheijm KR; Klooster R; Antoniou M; van der Maarel SM Am J Pathol; 2011 Oct; 179(4):1988-2000. PubMed ID: 21854744 [TBL] [Abstract][Full Text] [Related]
48. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. Chen S; Berthelier V; Yang W; Wetzel R J Mol Biol; 2001 Aug; 311(1):173-82. PubMed ID: 11469866 [TBL] [Abstract][Full Text] [Related]
49. Genetic heterogeneity in 30 German patients with oculopharyngeal muscular dystrophy. Müller T; Deschauer M; Kolbe-Fehr F; Zierz S J Neurol; 2006 Jul; 253(7):892-5. PubMed ID: 16619122 [TBL] [Abstract][Full Text] [Related]
50. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. Jaikaran ET; Higham CE; Serpell LC; Zurdo J; Gross M; Clark A; Fraser PE J Mol Biol; 2001 May; 308(3):515-25. PubMed ID: 11327784 [TBL] [Abstract][Full Text] [Related]
51. Animal model of oculopharyngeal muscular dystrophy. Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922 [TBL] [Abstract][Full Text] [Related]
53. PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. Shanmugam V; Dion P; Rochefort D; Laganière J; Brais B; Rouleau GA Ann Neurol; 2000 Nov; 48(5):798-802. PubMed ID: 11079546 [TBL] [Abstract][Full Text] [Related]
54. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy. Harish P; Malerba A; Dickson G; Bachtarzi H Hum Gene Ther; 2015 May; 26(5):286-92. PubMed ID: 25860803 [TBL] [Abstract][Full Text] [Related]
55. Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy. Richard P; Trollet C; Stojkovic T; de Becdelievre A; Perie S; Pouget J; Eymard B; Neurology; 2017 Jan; 88(4):359-365. PubMed ID: 28011929 [TBL] [Abstract][Full Text] [Related]
56. Nuclear compartmentalization and dynamics of the poly(A)-binding protein nuclear 1 (PABPN1) inclusions in supraoptic neurons under physiological and osmotic stress conditions. Villagra NT; Bengoechea R; Vaqué JP; Llorca J; Berciano MT; Lafarga M Mol Cell Neurosci; 2008 Mar; 37(3):622-33. PubMed ID: 18255312 [TBL] [Abstract][Full Text] [Related]
57. Identification of a novel mutation in a Korean patient with oculopharyngeal muscular dystrophy. Bae JS; Ki CS; Kim JW; Kim BJ J Clin Neurosci; 2007 Jan; 14(1):89-92. PubMed ID: 17138075 [TBL] [Abstract][Full Text] [Related]
58. Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis. Chartier A; Klein P; Pierson S; Barbezier N; Gidaro T; Casas F; Carberry S; Dowling P; Maynadier L; Bellec M; Oloko M; Jardel C; Moritz B; Dickson G; Mouly V; Ohlendieck K; Butler-Browne G; Trollet C; Simonelig M PLoS Genet; 2015 Mar; 11(3):e1005092. PubMed ID: 25816335 [TBL] [Abstract][Full Text] [Related]
59. Oculopharyngeal muscular dystrophy --an under-diagnosed disease in China? Report a China-born Chinese with PABPN1 mutation and epidemiology review of the literature. Chien YY J Formos Med Assoc; 2012 Jul; 111(7):397-402. PubMed ID: 22817818 [TBL] [Abstract][Full Text] [Related]
60. Mutation and haplotype analysis of oculopharyngeal muscular dystrophy in Thai patients. Pulkes T; Papsing C; Busabaratana M; Dejthevaporn C; Witoonpanich R J Clin Neurosci; 2011 May; 18(5):674-7. PubMed ID: 21316245 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]